Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zai Lab Limited - American Depositary Shares
(NQ:
ZLAB
)
25.31
-0.27 (-1.06%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zai Lab Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
Next >
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
September 29, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
August 17, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
August 06, 2026
From
Zai Lab Limited
Via
Business Wire
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
August 03, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
July 22, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
June 16, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
June 08, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Changes to Senior Leadership Team
May 21, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
May 11, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
May 07, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
April 22, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
April 18, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
April 17, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
April 01, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
March 17, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
February 26, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
February 10, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
January 06, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
December 23, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
December 08, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Updates to China’s National Reimbursement Drug List
December 07, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
November 06, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Participation in Investor Conferences in November and December 2025
October 31, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
October 24, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
October 15, 2025
From
Zai Lab Limited
Via
Business Wire
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 13, 2025
From
Zai Lab Limited
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB
September 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
September 01, 2025
From
Zai Lab Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
